Quarterly report pursuant to Section 13 or 15(d)

Schedule of Restricted Stock Award Activity (Details)

v3.23.1
Schedule of Restricted Stock Award Activity (Details) - Restricted Stock [Member]
 3 Months Ended
Mar. 31, 2023
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Restricted Stock Awards, Outstanding Beginning | shares 2,091,420 [1]
Weighted Average Grant Date Fair Value, Outstanding Beginning | $ / shares $ 11.44 [1]
Number of Restricted Stock Awards, Granted | shares
Weighted Average Grant Date Fair Value, Granted | $ / shares
Number of Restricted Stock Awards, Vested | shares (219,320)
Weighted Average Grant Date Fair Value, Vested | $ / shares $ 11.27
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Restricted Stock Awards, Outstanding Ending | shares 1,872,100
Weighted Average Grant Date Fair Value, Outstanding Ending | $ / shares $ 11.46
[1] The unvested restricted stock awards presented in the table above, are inclusive of 50,000 restricted stock awards granted outside the Lucid Diagnostics 2018 Equity Plan as of December 31, 2022. These 50,000 restricted stock awards were fully vested during the period ended March 31, 2023.